HUTCHMED (China) (HUTCHMED (China)) Dividends per Share : $0.00 (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) Dividends per Share?

HUTCHMED (China)'s dividends per share for the six months ended in Dec. 2023 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00. As of today, HUTCHMED (China)'s Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

HUTCHMED (China) Dividends per Share Historical Data

The historical data trend for HUTCHMED (China)'s Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) Dividends per Share Chart

HUTCHMED (China) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

HUTCHMED (China) Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of HUTCHMED (China)'s Dividends per Share

For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HUTCHMED (China)'s Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Dividend Yield % distribution charts can be found below:

* The bar in red indicates where HUTCHMED (China)'s Dividend Yield % falls into.

HUTCHMED (China) Dividends per Share Calculation

Dividends paid to per common share.

HUTCHMED (China) (NAS:HCM) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

HUTCHMED (China)'s Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.4
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

HUTCHMED (China) Dividends per Share Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

HUTCHMED (China) (HUTCHMED (China)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

00013:Hong Kong HCM.GB:UK HCM:UK H7T2:Germany

Address

2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG

Website

https://www.hutch-med.com

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.